caa a22 4500 469119462 CHVBK 20180323133134.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF02247425 doi (NATIONALLICENCE)springer-10.1007/BF02247425 Acute nicotinic blockade produces cognitive impairment in normal humans [Elektronische Daten] [Paul Newhouse, Alexandra Potter, June Corwin, Robert Lenox] Single oral doses of the central and peripheral nicotinic antagonist mecamylamine were administered to healthy young normal males in doses of 5, 10, and 20 mg in a placebo-controlled, double-blind study. The 20 mg dose caused a significant increase in errors in the learning condition of the Repeated Acquisition task, producing a slower acquisition curve. The lower doses produced less errors, but more than in the placebo condition. There was no effect of drug on the performance component (retrieval of previously learned information). On the recognition memory task, dose-related increases in false-alarms during the delay period were seen, with little effect on misses or hits. Reaction time measures suggested a dose-related slowing of RT on several tasks. Behavioral effects were minimal and physiologic measures were consistent with dose-related ganglionic blockade. We interpret these results to indicate that acute blockade of nicotinic receptor function can produce measurable and significant cognitive impairment, even in non-smoking normals. Springer-Verlag, 1992 Nicotine nationallicence Mecamylamine nationallicence Learning nationallicence Alzheimer's disease nationallicence Newhouse Paul Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut Potter Alexandra Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut Corwin June Division of Medical Psychology, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, and Research Service, Baltimore VAMC, Baltimore, MD, USA aut Lenox Robert Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut Psychopharmacology Springer-Verlag 108/4(1992-09-01), 480-484 0033-3158 108:4<480 1992 108 213 https://doi.org/10.1007/BF02247425 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247425 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Newhouse Paul Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut NATIONALLICENCE 700 1- Potter Alexandra Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut NATIONALLICENCE 700 1- Corwin June Division of Medical Psychology, Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, and Research Service, Baltimore VAMC, Baltimore, MD, USA aut NATIONALLICENCE 700 1- Lenox Robert Clinical Neuroscience Research Unit, Department of Psychiatry, University of Vermont College of Medicine, 1 South Prospect Street, 05401, Burlington, VT, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 108/4(1992-09-01), 480-484 0033-3158 108:4<480 1992 108 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer